Sports medicine journals publish three injectable peptide reviews

Three prominent orthopaedic and sports medicine journals have each published formal reviews of injectable peptide therapies within the past year, an unusual convergence that reflects how quickly demand for these compounds has outpaced the evidence base. The American Journal of Sports Medicine, Sports Medicine (Springer), and Sports Health all reached substantively similar conclusions: preclinical data is consistent and compelling, human safety and efficacy data is not, and clinicians need clearer guidance on what the evidence actually supports.

What the papers say

Mayfield and colleagues at the Keck School of Medicine of USC published a primer in the January 2026 American Journal of Sports Medicine (Vol. 54, Issue 1) aimed at orthopaedic physicians who are being asked by patients about peptide injections. The paper evaluates BPC-157, TB-500, CJC-1295 combined with ipamorelin, tesamorelin, and GHK-Cu, and concludes that while each shows tissue repair or anabolic signaling potential in preclinical models, the clinical evidence is insufficient to support recommendation for any indication. For BPC-157 specifically, the only published human data at the time of review was a single retrospective case series.

A separate review in Sports Medicine (Springer, 2026) by Mendias and colleagues examined both approved peptides — sermorelin, tesamorelin — and a wider set of unapproved compounds including BPC-157, TB-500, and GH secretagogues such as ipamorelin and CJC-1295. The paper notes a growing "gray market" of unapproved compounds that operate outside regulatory oversight and warns that rigorous human safety data are scarce, with potential for serious patient harm. Approved compounds had clearer dosing, pharmacokinetic, and adverse-event profiles; unapproved ones largely did not.

The third paper, a systematic review of BPC-157 in Sports Health (SAGE) by Vasireddi and colleagues, is the most focused. It screened 544 articles and included 36 studies — 35 preclinical and 1 clinical. The preclinical picture was consistent across models: accelerated healing in tendon, ligament, muscle, and bone, with VEGF upregulation and angiogenesis at injury sites appearing repeatedly. The single clinical study was a retrospective knee-pain series with 12 patients. The review found no adverse effects reported in any included study, but emphasized that the design quality of the clinical evidence does not support efficacy claims.

Why it matters

The simultaneous appearance of three peer-reviewed reviews in high-impact sports medicine journals is not coincidence — it reflects how dramatically peptide use has grown among athletes, trainers, and clinicians in the past two years. When patient demand precedes the evidence base by this wide a margin, the professional medical literature tends to catch up in clusters.

The consistent conclusion across all three papers — strong animal data, inadequate human data — carries two distinct implications. For the research community, it amounts to a call for properly designed trials: the preclinical rationale exists, and the gap is a human-evidence problem, not a mechanism problem. For clinicians, the message is more cautionary: the papers explicitly warn against extrapolating animal findings to patients, particularly given the uncontrolled sourcing and dosing typical of the current gray market.

All three reviews are published as the FDA moves toward its July PCAC meeting to evaluate BPC-157 and TB-500 for 503A compounding access. The literature record reviewed by the advisory committee will include this wave of papers.

What to watch

• Whether any sponsor files an IND based on the consistent preclinical rationale outlined across these reviews
• The FDA PCAC committee's treatment of systematic review evidence vs. RCT evidence when evaluating 503A candidacy
• Follow-on publications: each paper's reference to the inadequacy of current human data functions as a call for trials
• Whether the ASJM primer changes how orthopaedic practices discuss or document peptide use with patients

Sources

• Mayfield et al. — Injectable Peptide Therapy (ASJM, 2026)
• Mendias et al. — Safety and Efficacy of Peptide Therapies for Musculoskeletal Injuries (Sports Medicine, 2026)
• Vasireddi et al. — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (Sports Health, 2025)